Advent Life Sciences
Venture capitalActively deployingLondon · Seed–Late Stage · 24 people tracked
Investment thesis
Advent invests in exceptional scientific innovation in the biotech and medtech space, typically at seed or series A stages. The firm emphasizes a hands-on partnership model grounded in deep scientific and clinical expertise. The investment approach focuses on understanding the core innovation, assessing competitive positioning, maintaining transparent communication with founders, and collectively developing scientific, clinical, and operating strategies—alongside syndication and financing planning—to build leading biotech companies.
Source: firm website, verified Jul 21, 2026.
Team · 24 people
from the firm's website
What they invest in
from 2 of 86 portfolio companiesBiotech ×1Healthtech ×1Medical Devices ×1
HQs:United States×2
Investments · showing 60 of 86
founders shown can be your intro pathGlycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)
Board seats · per SEC filings
what is this? ⓘ$19M raise · filed May 2026 · via Alan E. Walts, Alan W. Walts, Alan Walts, Raj E. Parekh, Raj Parekh, Raj W. Parekh
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Advent Life Sciences invest at?
- Advent Life Sciences invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Advent Life Sciences focus on?
- Advent Life Sciences focuses on Biotech, Medical Devices.
- Where is Advent Life Sciences located?
- Advent Life Sciences is headquartered in London, GB.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.
Osage University Partners is a venture capital firm founded in 2009 that invests in breakthrough startups emerging from leading research labs and university innovation ecosystems. The firm focuses on technology (software, hardware, climate tech) and life science (therapeutics, medtech, diagnostics, research tools) companies across all stages from pre-seed through crossover, leveraging partnerships with over 150 universities and research institutions globally.